Results 91 to 100 of about 14,172 (227)

Molecular Mechanisms of Resistance and Treatment Efficacy of Delamanid Against Mycobacterium tuberculosis: A Systematic Review

Health Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background and Aims Tuberculosis (TB) remains a major global health problem, and treatment progress is increasingly threatened by rising multidrug‐resistant tuberculosis (MDR‐TB). Delamanid (DLM), a nitroimidazole drug, has shown good efficacy and safety against both drug‐susceptible and drug‐resistant Mycobacterium tuberculosis (Mtb) strains.
Md. Mahmudul Islam, Md. Zahid Hasan, Md. Touki Tahamid Tusar, Md. Yeamin Hossain, Md. Motaher Hossain, Md. Abdulla Al Jubayed, Md. Jubaer‐Al‐Abedin, Sheikh Soikot, Shanzida Akther, Jahid Bhuyian, Hafizur Rahman Gazi, B. M. Mahmudul Hasan, Md. Shofiul Azam, Md. Enamul Haque, Abdullah‐Al‐Jubayer, Md. Faruk Hasan, F. M. Ali Haydar, Md. Khalekuzzaman, Md. Torequl Islam, Sohel Hasan   +19 more
wiley   +1 more source

Randomized, Placebo‐Controlled, First‐in‐Human Study of the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Oral Doses of Novel Antitubercular Drug Candidate, GSK2556286, in Healthy Adults

The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract This first‐in‐human study (ClinicalTrials.gov identifier: NCT04472897) evaluated the safety, tolerability, pharmacokinetics, and food effect of single ascending and repeat oral doses of GSK2556286 (GSK286), a novel antitubercular drug candidate with efficacy in animal models of tuberculosis.
Emma Ilsley, Edward Banham‐Hall, Tetyana Chaychenko, Katerina Chinenyeze, Gareth Maher‐Edwards, Catherine Muya, Katie Rolfe, Raman Sharma, Simon Tiberi, David Barros‐Aguirre   +9 more
wiley   +1 more source

High isoniazid resistance rates in rifampicin susceptible Mycobacterium tuberculosis pulmonary isolates from Pakistan.

PLoS ONE, 2012
BackgroundRapid new diagnostic methods (including Xpert MTB/RIF assay) use rifampicin resistance as a surrogate marker for multidrug resistant tuberculosis. Patients infected with rifampicin susceptible strains are prescribed first line anti-tuberculosis
Naima Fasih, Yasraba Rafiq, Kausar Jabeen, Rumina Hasan   +3 more
doaj   +1 more source

Genome analysis of multi- and extensively-drug-resistant tuberculosis from KwaZulu-Natal, South Africa. [PDF]

PLoS ONE, 2009
The KZN strain family of Mycobacterium tuberculosis is a highly virulent strain endemic to the KwaZulu-Natal region of South Africa, which has recently experienced an outbreak of extensively-drug resistant tuberculosis.
Thomas R Ioerger, Sunwoo Koo, Eun-Gyu No, Xiaohua Chen, Michelle H Larsen, William R Jacobs, Manormoney Pillay, A Willem Sturm, James C Sacchettini   +8 more
doaj   +1 more source

An Interactive Pharmacokinetic‐Pharmacodynamic Framework to Evaluate Bedaquiline Dose Modifications in Adults With Tuberculosis

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 5, May 2026.
ABSTRACT Bedaquiline is approved for use in a thrice‐weekly dosing schedule; simpler once‐daily dosing strategies could enable fixed‐dose combinations and improve patient adherence. We developed an interactive R Shiny simulation tool to enable the evaluation of different bedaquiline dosing schedules within an integrated dose‐pharmacokinetic‐efficacy ...
Yu‐Jou Lin, Frances Okibedi, Mats O. Karlsson, Elin M. Svensson   +3 more
wiley   +1 more source

Preventive chemotherapy in children exposed to multiple drug resistant tuberculosis

Туберкулез и болезни лёгких, 2019
The objective of the study: to assess the safety and efficacy of preventive anti-tuberculosis treatment of children exposed to multiple drug resistant tuberculosis (MDR TB) using different combinations of anti-tuberculosis drugs.Subjects and methods. 150
V. A. Аksenova, N. I. Klevno, A. V. Kazakov, A. V. Gordina, R. Kh. Fatykhova   +4 more
doaj   +1 more source

Gaining insights into MmpL3: combining structural and computational approaches to unlock transport and inhibitor‐binding mechanisms

Acta Crystallographica Section D, Volume 82, Issue 5, Page 550-570, May 2026.
This study investigates the mycobacterial membrane protein MmpL3, a key target for new antituberculosis drugs, by combining high‐resolution crystallography and computational simulations. It reveals how the inhibitor UPAR‐1109 binds to MmpL3, providing detailed insights into the function and flexibility of the protein and supporting the rational design ...
Satoshi Murakami, Domenico Marson, Eiki Yamashita, Bruno Broshka, Ui Okada, Maho Aoki, Giannamaria Annunziato, Erik Laurini, Emanuele Carosati, Marco Pieroni   +9 more
wiley   +1 more source

Prevalence of resistance to levofloxacin and pyrazinamide among new and previously treated isoniazid-resistant, rifampicin-susceptible TB (Hr-TB) cases. [PDF]

, 2020
Prevalence of resistance to levofloxacin and pyrazinamide among new and previously treated isoniazid-resistant, rifampicin-susceptible TB (Hr-TB) cases.
Nazir Ismail (602087), Katherine Floyd (65595), Maria Cecilia G. Ama (8338896), Philippe Glaziou (157315), Daniela Maria Cirillo (8338884), Dennis Falzon (122428), Anna S. Dean (8338878), Claudio U. Köser (8338887), Alena Skrahina (5504123), Sabira Tahseen (849369), S. M. Mostofa Kamal (8338902), Natavan Alikhanova (8338899), Matteo Zignol (94959), Lice Y. Gonzalez-Angulo (8338890), Olga Tosas-Auget (8338893), Andrea Maurizio Cabibbe (8338881)   +15 more
core   +1 more source

Cutaneous non‐tuberculous mycobacterial infections: A retrospective study of 94 cases from Germany

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 5, Page 608-617, May 2026.
Summary Background Cutaneous non‐tuberculous mycobacterial infections (NTM) remain a diagnostic and therapeutic challenge. The aim of this study was to characterize cutaneous NTM infections in Germany over a 24‐year‐period. Patients and Methods 73 patients with cutaneous NTM infections diagnosed at 17 different German University Hospitals from 2000 ...
Luisa Bopp, Nicolai Deresz, Henning Klapproth, Isabelle Suárez, Jonathan Jantsch, Mario Fabri, Esther von Stebut   +6 more
wiley   +1 more source

Applicability of the shorter ‘Bangladesh regimen’ in high multidrug-resistant tuberculosis settings

International Journal of Infectious Diseases, 2017
In spite of the recent introduction of two new drugs (delamanid and bedaquiline) and a few repurposed compounds to treat multidrug-resistant and extensively drug-resistant tuberculosis (MDR- and XDR-TB), clinicians are facing increasing problems in ...
Giovanni Sotgiu, Simon Tiberi, Rosella Centis, Lia D’Ambrosio, Zhenia Fuentes, Alimuddin Zumla, Giovanni Battista Migliori   +6 more
doaj   +1 more source